Spectral AI Q3 research revenue falls 24.7% to $2.86M
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Spectral AI, Inc. (MDAI) reported third-quarter 2026 research and development revenue of $2.856 million, down 24.7% year over year, and a net loss of $3.656 million versus $3.552 million. Gross margin was 27.2%, 15.5 percentage points lower. For the first nine months, revenue was $10.371 million versus $15.564 million, net loss was $11.244 million versus $8.623 million, and operating cash use was $10.472 million versus $7.368 million.
The FDA granted De Novo Classification for DeepView on May 26, 2026, authorizing U.S. commercial distribution; the company had generated no product revenue as of September 30, 2026. Management said that, based on its current operating plan, $11.2 million in cash, $24.8 million of remaining committed BARDA funding, 3,657,945 Yorkville SEPA shares available for issuance, and up to $15.0 million in additional SEPA sales provide sufficient liquidity for at least one year. SEPA access is subject to purchase-price, ownership, exchange-cap and shelf-capacity limits.
Debt outstanding was $15.5 million as of September 30, 2026. Management reported ineffective disclosure controls due to a material weakness in the financial-statement close process; remediation measures are underway, and management plans to test controls for the third and fourth quarters of 2026.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Major pointFDA De Novo classification authorized U.S. commercial distribution on May 26, 2026.
Negative
- Major pointMaterial weakness left disclosure controls ineffective as of September 30, 2026.
- Moderate pointResearch revenue fell 24.7% in Q3 and 33.4% over nine months.
- Moderate pointNine-month net loss widened to $11.244 million from $8.623 million.
- Moderate pointQ3 gross margin fell 15.5 percentage points to 27.2%.
- Moderate pointNine-month operating cash use rose to $10.472 million from $7.368 million.
Filing Explained
From
Key Figures
Key Terms
De Novo Classification regulatory
UKCA marking regulatory
standby equity purchase agreement financial
cost-share provisions financial
New Technology Ambulatory Payment Classification medical
Level 3 financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did MDAI report for third-quarter 2026 revenue and net loss?
How long does MDAI say its available liquidity will fund operations?
What regulatory status did MDAI's DeepView system receive?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(MARK ONE)
For the quarterly period ended
For the transition period from to
Commission file number:
(Exact Name of Registrant as Specified in Its Charter)
| (State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
(Address of principal executive offices)
(Issuer’s telephone number)
Securities registered pursuant to Section 12(b) of the Exchange Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The | ||||
| The |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large Accelerated Filer | ☐ | Accelerated Filer | ☐ |
| ☒ | Smaller Reporting Company | ||
| Emerging Growth Company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No
As of November 16, 2026, there were
SPECTRAL AI, INC.
FORM 10-Q FOR THE QUARTER ENDED SEPTEMBER 30, 2026
TABLE OF CONTENTS
| Page | ||
| Part I. Financial Information | 1 | |
| Item 1. Interim Financial Statements | 1 | |
| Unaudited Condensed Consolidated Balance Sheets as of September 30, 2026 and December 31, 2025 | 1 | |
| Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2026 and 2025 | 2 | |
| Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Deficit for the three and nine months ended September 30, 2026 and 2025 | 3 | |
| Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2026 and 2025 | 4 | |
| Notes to Unaudited Condensed Consolidated Financial Statements | 5 | |
| Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations | 19 | |
| Item 3. Quantitative and Qualitative Disclosures About Market Risk | 26 | |
| Item 4. Controls and Procedures | 27 | |
| Part II. Other Information | ||
| Item 1. Legal Proceedings | 28 | |
| Item 1A. Risk Factors | 28 | |
| Item 2. Unregistered Sales of Equity Securities and Use of Proceeds | 28 | |
| Item 3. Defaults Upon Senior Securities | 28 | |
| Item 4. Mine Safety Disclosures | 29 | |
| Item 5. Other Information | 29 | |
| Item 6. Exhibits | 29 | |
| Part III. Signatures | 30 | |
i
Cautionary Note Regarding Forward-Looking Statements
This Quarterly Report on Form 10-Q contains statements that are forward-looking and as such are not historical facts, including statements regarding our strategy, plans, objectives, initiatives, expected commercialization activities and financial outlook. These statements constitute projections, forecasts and forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.
The forward-looking statements contained in this Quarterly Report are based on our current expectations and beliefs concerning future developments and their potential effects on us. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements involve a number of risks and uncertainties, some of which are beyond our control, that may cause actual results or performance to differ materially from those expressed or implied by these statements. Investors should carefully consider the risks and uncertainties described in Item 1A, Risk Factors, of our Annual Report on Form 10-K for the year ended December 31, 2025 and in our other filings with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
ii
PART I - FINANCIAL INFORMATION
Item 1. Interim Financial Statements
SPECTRAL AI, INC.
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | $ | ||||||
| Accounts receivable, net | ||||||||
| Inventory | ||||||||
| Prepaid expenses | ||||||||
| Other current assets | ||||||||
| Total current assets | ||||||||
| Non-current assets: | ||||||||
| Property and equipment, net | ||||||||
| Right-of-use assets | ||||||||
| Other assets | ||||||||
| Total Assets | $ | $ | ||||||
| Liabilities and Stockholders’ Deficit | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | $ | ||||||
| Accrued expenses | ||||||||
| Deferred revenue | ||||||||
| Lease liabilities, short-term | ||||||||
| Notes payable | ||||||||
| Warrant liabilities | ||||||||
| Total current liabilities | ||||||||
| Notes payable, long-term | ||||||||
| Lease liabilities, long-term | ||||||||
| Total Liabilities | ||||||||
| Commitments and contingencies (Note 8) | ||||||||
| Stockholders’ Deficit | ||||||||
| Preferred stock ($ | - | - | ||||||
| Common stock ($ | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated other comprehensive income | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Total Stockholders’ Deficit | ( | ) | ( | ) | ||||
| Total Liabilities and Stockholders’ Deficit | $ | $ | ||||||
The accompanying notes are an integral part of these condensed consolidated financial statements
1
SPECTRAL AI, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except share and per share data)
| Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Research and development revenue | $ | $ | $ | $ | ||||||||||||
| Cost of revenue | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Gross profit | ||||||||||||||||
| Operating costs and expenses: | ||||||||||||||||
| Research and development | ||||||||||||||||
| General and administrative | ||||||||||||||||
| Selling and marketing | ||||||||||||||||
| Total operating costs and expenses | ||||||||||||||||
| Operating loss | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Net interest expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Financing related costs | ( | ) | - | ( | ) | ( | ) | |||||||||
| Change in fair value of warrant liability | ( | ) | ||||||||||||||
| Change in fair value of notes payable | - | - | - | |||||||||||||
| Foreign exchange transaction loss, net | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Total other income (expense), net | ( | ) | ( | ) | ( | ) | ||||||||||
| Loss before income taxes | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Income tax benefit (provision) | ( | ) | ( | ) | ( | ) | ||||||||||
| Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Net loss per share of common stock | ||||||||||||||||
| Basic and Diluted | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Weighted average common shares outstanding | ||||||||||||||||
| Basic and Diluted | ||||||||||||||||
| Other comprehensive income (loss): | ||||||||||||||||
| Foreign currency translation adjustments | $ | $ | ( | ) | $ | ( | ) | $ | ||||||||
| Total comprehensive loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
The accompanying notes are an integral part of these condensed consolidated financial statements
2
SPECTRAL AI, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT
(In thousands, except share data)
| Common Stock | Additional Paid-in |
Accumulated Other Comprehensive |
Accumulated | Total Stockholders’ |
||||||||||||||||||||
| Shares | Amount | Capital | Income | Deficit | Deficit | |||||||||||||||||||
| Balance at December 31, 2025 | $ | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||
| Stock-based compensation | - | - | - | - | ||||||||||||||||||||
| Stock option exercises | - | - | - | |||||||||||||||||||||
| Settlement of restricted stock units | - | - | - | - | - | |||||||||||||||||||
| Cumulative translation adjustment | - | - | - | ( | ) | - | ( | ) | ||||||||||||||||
| Pre-funded warrant exercises | - | - | - | - | - | |||||||||||||||||||
| Net loss | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||
| Balance at March 31, 2026 | ( | ) | ( | ) | ||||||||||||||||||||
| Stock-based compensation | - | - | - | - | ||||||||||||||||||||
| Stock option exercises | - | - | - | |||||||||||||||||||||
| Issuance of common stock under the SEPA | - | - | - | |||||||||||||||||||||
| Vesting of restricted stock units | - | - | - | - | - | |||||||||||||||||||
| Cumulative translation adjustment | - | - | - | ( | ) | - | ( | ) | ||||||||||||||||
| Warrant exercises | - | - | - | |||||||||||||||||||||
| Net loss | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||
| Balance at June 30, 2026 | ( | ) | ( | ) | ||||||||||||||||||||
| Stock-based compensation | - | - | - | - | ||||||||||||||||||||
| Cumulative translation adjustment | - | - | - | - | ||||||||||||||||||||
| Net loss | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||
| Balance at September 30, 2026 | ( | ) | ( | ) | ||||||||||||||||||||
| Common Stock | Additional Paid-in |
Accumulated Other Comprehensive |
Accumulated | Total Stockholders’ |
||||||||||||||||||||
| Shares | Amount | Capital | Income | Deficit | Deficit | |||||||||||||||||||
| Balance at December 31, 2024 | $ | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||
| Stock-based compensation | - | - | - | - | ||||||||||||||||||||
| Issuance of Common Stock from debt offering (net of $ | - | - | - | |||||||||||||||||||||
| Issuance of common stock to pay convertible debt | - | - | - | |||||||||||||||||||||
| Sale of common stock (net of $ | - | - | ||||||||||||||||||||||
| Exercise of stock options | - | - | ||||||||||||||||||||||
| Cumulative translation adjustment | - | - | - | - | ||||||||||||||||||||
| Net income | - | - | - | - | ||||||||||||||||||||
| Balance at March 31, 2025 | $ | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||
| Stock-based compensation | - | - | - | - | ||||||||||||||||||||
| Issuance of common stock from debt offering | - | - | - | - | - | |||||||||||||||||||
| Vesting of restricted stock units | - | - | - | - | - | |||||||||||||||||||
| Cumulative translation adjustment | - | - | - | - | ||||||||||||||||||||
| Net loss | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||
| Balance at June 30, 2025 | ( | ) | ( | ) | ||||||||||||||||||||
| Stock-based compensation | - | - | - | - | ||||||||||||||||||||
| Exercise of stock options | - | - | - | |||||||||||||||||||||
| Exercise of warrants | - | - | ||||||||||||||||||||||
| Cumulative translation adjustment | - | - | - | ( | ) | - | ( | ) | ||||||||||||||||
| Net loss | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||
| Balance at September 30, 2025 | ( | ) | ( | ) | ||||||||||||||||||||
The accompanying notes are an integral part of these condensed consolidated financial statements
3
SPECTRAL AI, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
| Nine Months Ended September 30, |
||||||||
| 2026 | 2025 | |||||||
| Cash flows from operating activities: | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation expense | ||||||||
| Amortization of debt issuance costs | ||||||||
| Stock-based compensation | ||||||||
| Amortization of right-of-use assets | ||||||||
| Change in fair value of warrant liabilities | ( | ) | ||||||
| Change in fair value of notes payable | - | ( | ) | |||||
| Issuances of shares for borrowing related costs | - | |||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | ( | ) | ||||||
| Inventory | ( | ) | ( | ) | ||||
| Prepaid expenses | ||||||||
| Other assets | ( | ) | ||||||
| Accounts payable | ( | ) | ( | ) | ||||
| Accrued expenses | ( | ) | ( | ) | ||||
| Deferred revenue | ( | ) | ||||||
| Lease liabilities | ( | ) | ( | ) | ||||
| Net cash used in operating activities | ( | ) | ( | ) | ||||
| Cash flows from financing activities: | ||||||||
| Proceeds from issuance of common stock and warrants | ||||||||
| Proceeds from notes payable | ||||||||
| Payments for notes payable | ( | ) | ( | ) | ||||
| Proceeds from warrant exercises | ||||||||
| Stock option exercises | ||||||||
| Net cash provided by financing activities | ||||||||
| Effect of exchange rate changes on cash and cash equivalents | ( | ) | ||||||
| Net (decrease) increase in cash and cash equivalents | ( | ) | ||||||
| Cash and cash equivalents, beginning of period | ||||||||
| Cash and cash equivalents, end of period | $ | $ | ||||||
| Supplemental cash flow information: | ||||||||
| Cash paid for interest | $ | $ | ||||||
| Cash paid for taxes | $ | $ | ||||||
| Noncash investing and financing activities disclosure: | ||||||||
| Tenant improvement allowance payments made by the lessor directly to a third party | $ | - | $ | ( | ) | |||
| Issuance of common stock to settle notes payable | $ | - | $ | |||||
| Insurance premiums financed through notes payable | $ | $ | - | |||||
The accompanying notes are an integral part of these condensed consolidated financial statements
4
SPECTRAL AI, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
1. NATURE OF THE BUSINESS AND PRESENTATION
Overview
Spectral AI, Inc., a Delaware corporation (the “Company”) is an Artificial Intelligence (“AI”) company focused on predictive medical diagnostics. Our DeepViewTM System uses proprietary AI algorithms to distinguish between healthy, partially damaged and fully damaged human tissue characteristics invisible to the naked eye, at the initial time of wound presentation. The DeepView System delivers a binary prediction on the wound’s capacity to heal or not-heal by a specified time in the future. Our DeepView System’s output is specifically engineered to assist the physician in making a more accurate, timely and informed diagnostic decision regarding the treatment of the patient’s wounds. Our focus is on our burn indication.
In February 2024, our DeepView System, comprised of the multispectral imaging component integrated with the predictive AI-Burn software component, received United Kingdom Conformity Assessed (“UKCA”) marking for use in the United Kingdom for burn indications. In June 2025, we filed a De Novo application for the DeepView System with the United States Food and Drug Administration (“FDA”) so that it may achieve Class II medical device designation. On May 26, 2026, the FDA granted De Novo Classification for the DeepView System allowing the Company to commence commercial distribution activities in the United States.
The Company has not generated any product revenue to date. The Company currently generates revenue from contract development and research services by providing such services to governmental agencies, primarily to the Biomedical Advanced Research and Development Authority (“BARDA”) and under a contract with the Medical Technology Enterprise Consortium (“MTEC”).
We have received substantial support from the U.S. government for our DeepView System’s application for burn wounds from BARDA. On September 27, 2023, the Company executed a new contract with BARDA, providing the Company with additional funding of up to approximately $
Basis of Presentation
The Company’s condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“GAAP”) as determined by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) or an Accounting Standards Update (“ASU”).
These condensed consolidated financial statements should be read in conjunction with the financial statements and notes included in the Company’s audited consolidated financial statements as of and for the years ended December 31, 2025 and 2024. The condensed consolidated balance sheet as of December 31, 2025 included herein was derived from the audited consolidated financial statements as of that date.
5
The accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, and cash flows for the interim periods. The results for the nine months ended September 30, 2026 are not necessarily indicative of the results to be expected for any subsequent quarter, the year ending December 31, 2026, or any other period.
Beginning on April 1, 2026, the Company changed the presentation of certain costs on its condensed consolidated statement of operations. This voluntary change in classification of certain research and development and selling and marketing costs, resulted in a decrease in general and administrative expenses and offsetting increases in research and development and selling and marketing costs. Selling and marketing expense consists primarily of personnel-related costs associated with the Company’s commercial organization, allocated facilities costs, and commercialization readiness activities, including external consulting services, market access initiatives, and pricing studies. Refer to Note 3 for details of the composition of research and development expense. The Company believes this presentation is preferable as it will provide greater transparency regarding its operating expenses and aligns with how the business is managed.
In addition, the Company reclassified the amortization of debt issuance costs from financing related costs to net interest expense on its condensed consolidated statement of operations. The reclassification increased net interest expense and decreased financing related costs by $
These changes in classification have been applied retrospectively to all periods presented. These changes in presentation had no impact on revenue, cost of revenue, loss from operations, income (loss) before income taxes, income tax provision (benefit), net income (loss), earnings (loss) per common share, or other components of equity or cash flows. In addition, other expense information disclosed in Note 13 – Segment Information was adjusted for these changes.
Except as described elsewhere in Note 2 under the heading “Recently adopted accounting pronouncements,” there have been no material changes to the Company’s significant accounting policies as described in the audited consolidated financial statements as of December 31, 2025.
Principles of Consolidation
The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Spectral MD Holdings LLC, Spectral MD, Inc., Spectral MD UK Limited, and Spectral IP, Inc. (“Spectral IP”). Inter-company transactions and balances have been eliminated in consolidation.
Use of Estimates
The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, revenue recognition (including the measure of progress of completion), warrant liabilities, the fair value of certain debt, stock-based compensation expense, stock issued for transaction costs, the net realizable value of inventory, right-of-use assets, and income tax valuation allowances. Actual results could differ from these estimates.
6
Concentrations of Credit Risk
Financial instruments which potentially subject the Company to credit risk consist principally of cash and cash equivalents and accounts receivable. Substantially all cash and cash equivalents are held in US financial institutions which, at times, exceed federally insured limits. The Company has not recognized any losses from credit risks on such accounts. The Company believes it is not exposed to significant credit risk on cash and cash equivalents.
Additional credit risk is related to the Company’s concentration of accounts receivable. As of September 30, 2026 and December 31, 2025, accounts receivable were concentrated in one customer (which is a U.S. government agency) representing
One customer (which is a U.S. government agency) accounted for
Risks and Uncertainties
The Company is subject to a number of risks common to development stage companies in the medical technology industry, including, but not limited to, risks of failure of preclinical studies and clinical trials, dependence on key personnel, protection of proprietary technology, reliance on third party organizations, risks of obtaining regulatory approval for any products that it may develop, development by competitors of technological innovations, compliance with government regulations and the need to obtain additional financing.
Liquidity
As of September 30, 2026 and December 31, 2025, the Company had $
BARDA has committed $
As of September 30, 2026, based on our current operating plan, our cash and cash equivalents of $
We have based this determination on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. Changing circumstances could also cause us to consume capital significantly faster than we currently anticipate, and we may need to raise capital sooner or in greater amounts than currently expected because of circumstances beyond our control. To the extent additional capital is necessary, there are no assurances that we will be able to raise additional capital on favorable terms or at all, and therefore we may not be able to execute our business plans and the continued work on indications beyond expanding our burn indication.
2. RECENT ACCOUNTING PRONOUNCEMENTS
Recently Adopted Accounting Standards
In July 2025, the FASB issued ASU No. 2025-05, Measurement of Credit Losses for Accounts Receivable and Contract Assets, (“ASU 2025-05”) which provides a practical expedient to measure credit losses on accounts receivable and contract assets. The Company adopted this guidance prospectively in the three months ended March 31, 2026. The adoption of ASU 2025-05 did not have a material impact on the consolidated financial statements and related disclosures.
7
Recently Issued Accounting Standards
In October 2023, the FASB issued ASU 2023-06 Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative (“ASU 2023-06”), which modifies certain disclosure and presentation requirements of a variety of Topics in the Codification and is intended to both clarify or improve such requirements and align the requirements with the SEC’s regulations. The effective date for each amendment is the effective date of the removal of the related disclosure from Regulation S-X or Regulation S-K, with early adoption prohibited. The Company will apply the provisions prospectively as such provisions become effective and does not expect ASU 2023-06 to have a material impact on the consolidated financial statements.
In November 2024, the FASB issued ASU No. 2024-03, Income Statement- Reporting Comprehensive Income- Expense Disaggregation Disclosures (Subtopic 220-40), requiring public business entities to disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The disclosures required under the guidance can be applied either prospectively to financial statements issued for reporting periods after the effective date or retrospectively to any or all periods presented in the financial statements. The Company is currently evaluating the impact of adopting this guidance on its consolidated financial statements and disclosures.
Emerging Growth Company Status
The Company will no longer be an emerging growth company as of December 31, 2026 and, as a result, the Company will no longer be able to take advantage of reduced disclosure and other obligations that are available to emerging growth companies after that date.
3. RESEARCH AND DEVELOPMENT REVENUE
For the three and nine months ended September 30, 2026 and 2025, the Company’s revenues disaggregated by the major sources were as follows (in thousands):
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| BARDA | $ | $ | $ | $ | ||||||||||||
| Other U.S. governmental authorities | ||||||||||||||||
| Total revenue | $ | $ | $ | $ | ||||||||||||
The following table presents the activity in the Company’s contract liabilities during the nine months ended September 30, 2026 (in thousands):
| December 31, 2025 Balance | Additions | Reductions | September 30, 2026 Balance | |||||||||||||
| Contract liabilities: | ||||||||||||||||
| Deferred revenue | $ | $ | $ | ( | ) | $ | ||||||||||
| Total contract liabilities | $ | $ | $ | ( | ) | $ | ||||||||||
8
Unbilled revenue is included in other current assets in the condensed consolidated balance sheets.
| December 31, 2025 Balance | Additions | Reductions | September 30, 2026 Balance | |||||||||||||
| Contract assets: | ||||||||||||||||
| Unbilled revenue | $ | $ | $ | ( | ) | $ | ||||||||||
| Total contract assets | $ | $ | $ | ( | ) | $ | ||||||||||
As of September 30, 2026, the aggregate amount of the transaction price allocated to the Company’s remaining performance obligations under its PBS BARDA Contract was approximately $
Research and Development Expense
The Company expenses research and development costs as incurred. These expenses include salaries for research and development personnel, consulting fees, product development, pre-clinical studies, clinical trial costs, and other fees and costs related to the development of our technology.
For the three and nine months ended September 30, 2026, research and development expense was $
4. INVENTORY, PREPAID EXPENSES AND OTHER CURRENT ASSETS
The following tables summarize the components of inventory, prepaid expenses and other current assets as of September 30, 2026 and December 31, 2025 (in thousands):
Inventory
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Finished goods | $ | $ | ||||||
| Parts held at contract manufacturer | - | |||||||
| Total inventory | $ | $ | ||||||
Prepaid Expenses
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Prepaid insurance | $ | $ | ||||||
| Prepaid software & subscriptions | ||||||||
| Other | ||||||||
| Total prepaid expenses | $ | $ | ||||||
9
Other Current Assets
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Unbilled revenue | $ | $ | ||||||
| Deposits | ||||||||
| VAT recoverable | ||||||||
| Other | - | |||||||
| Total other current assets | $ | $ | ||||||
5. ACCRUED EXPENSES
Accrued expenses consist of the following as of September 30, 2026, and December 31, 2025 (in thousands):
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Salary and wages | $ | $ | ||||||
| Operating expenses | ||||||||
| Benefits | ||||||||
| Non-operating expenses | - | |||||||
| Taxes | ||||||||
| Total accrued expenses | $ | $ | ||||||
6. NOTES PAYABLE
The Company entered into the Avenue Financing (defined below) and financing arrangements for a portion of its Directors and Officers insurance premiums, as follows (in thousands):
| Principal Repayments | Outstanding Balance | |||||||||||||||||||||||
| Amount | Nine Months Ended September 30, | September 30, | December 31, | |||||||||||||||||||||
| Financed | Interest Rate | 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||
| Avenue Capital Note Principal and Final Payment Fee | $ | Prime + | % | $ | - | $ | - | $ | $ | |||||||||||||||
| Yorkville Convertible Notes, at fair value | % | - | - | - | ||||||||||||||||||||
| 2026 Insurance Note | % | - | - | - | ||||||||||||||||||||
| 2025 Insurance Note | % | - | - | |||||||||||||||||||||
| 2024 Insurance Note | % | - | - | - | ||||||||||||||||||||
| $ | $ | $ | $ | |||||||||||||||||||||
| Less: current portion of notes payable | ( | ) | ( | ) | ||||||||||||||||||||
| Unamortized debt discounts and debt issuance costs | ( | ) | ( | ) | ||||||||||||||||||||
| Notes payable, long term | $ | $ | ||||||||||||||||||||||
Avenue Capital Financing
On March 24, 2025, the Company completed the Avenue Financing, with an initial draw-down of $
10
The term of the financing with Avenue Capital Group (the “Avenue Financing”) is for three years, with an interest-only payment period of no less than 15 months, which was extended to 24 months upon the Company’s achievement of the milestones for the second financing tranche during the three months ended June 30, 2026. The second financing tranche, which includes an additional $
Up to $
As part of the Avenue Financing the Company issued
On June 18, 2026, the Company drew down the second financing tranche under the Avenue Financing following the achievement of the required funding conditions. The Company received proceeds of $
Repayment of Yorkville Convertible Notes
During the nine months ended September 30, 2025, the Company paid the remaining $
Insurance Notes
The Company finances its annual directors’ and officers’ insurance premiums. In September 2026, the Company financed $
7. WARRANT LIABILITIES
The following table summarizes the Company’s outstanding warrants classified as liabilities as of September 30, 2026 (fair value in thousands):
| September 30, 2026 | ||||||||||||||||
| Warrant | Issue Date | Expiration | Exercise Price | Warrants Outstanding | Fair Value | |||||||||||
| Public Warrants | $ | |||||||||||||||
| Investor Warrants | $ | |||||||||||||||
| Avenue Warrants | $ | |||||||||||||||
| Hudson warrants | $ | |||||||||||||||
| Dominari warrants | $ | |||||||||||||||
| $ | ||||||||||||||||
11
In September 2023, in conjunction with the business combination with Rosecliff Acquisition Corp I (the “Business Combination”), the Company assumed the public warrants which had an exercise price of $
On June 16, 2021, the Company issued
Investor Warrants: On March 21, 2025, the Company entered into the purchase agreements with certain stockholders for the sale of an aggregate of
During the year ended December 31, 2025,
Avenue Warrants: On March 24, 2025, the Company completed the Avenue Financing, with an initial draw-down of $
As of September 30, 2026, there were
Hudson Warrants: On October 22, 2025, the Company entered into a securities purchase agreement with a certain investor for the sale of
12
During the nine months ended September 30, 2026,
Dominari Warrants: On October 28, 2025, in connection with the Hudson Bay financing, the Company issued warrants to purchase
The Company accounts for its Public Warrants, Investor Warrants, Avenue Warrants, Hudson Warrants and Dominari Warrants as derivative liabilities. Accordingly, the Company recognizes the instruments as liabilities at fair value, and adjusts the instruments to fair value at the end of each reporting period. The liabilities are subject to re-measurement at each balance sheet date until exercised, redeemed or expired, and any change in fair value is recognized in the Company’s consolidated statements of operations within other income (expense).
Fair Value Measurements
The following table presents information about the Company’s financial liabilities that are measured at fair value on a recurring basis as of September 30, 2026 and December 31, 2025, by level within the fair value hierarchy (in thousands):
| Fair value measured as of September 30, 2026 | ||||||||||||||||
| Fair value at September 30, 2026 | Quoted prices in active markets (Level 1) | Significant other observable inputs (Level 2) | Significant unobservable inputs (Level 3) | |||||||||||||
| Warrant liabilities | $ | - | ||||||||||||||
| Fair value measured as of December 31, 2025 | ||||||||||||||||
| Fair value at December 31, 2025 | Quoted prices in active markets (Level 1) | Significant other observable inputs (Level 2) | Significant unobservable inputs (Level 3) | |||||||||||||
| Warrant liabilities | $ | $ | $ | - | $ | |||||||||||
There were no transfers between Level 1, 2 or 3 during the nine months ended September 30, 2026.
Fair values of cash and cash equivalents, accounts receivable, accounts payable, accrued expenses, and short-term debt are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The fair value of the Public Warrants, which trade in active markets, is based on quoted market prices and classified in Level 1 of the fair value hierarchy. The Angel Warrants, Avenue Warrants, Investor Warrants, Dominari Warrants, and Hudson Warrants are classified within Level 3 of the fair value hierarchy because their fair values are based on significant inputs that are unobservable in the market.
13
The fair value of the Avenue Warrants at September 30, 2026 was estimated using a Black-Scholes option pricing model. The fair value of the Investor Warrants, Dominari Warrants, and Hudson Warrants were estimated using a simulation model.
The following table presents changes in Level 3 liabilities measured at fair value for the nine months ended September 30, 2026 and 2025 (in thousands):
| Balance - January 1, 2025 | $ | |||
| Fair value at issuance | ||||
| Change in fair value | ( | ) | ||
| Balance - March 31, 2025 | $ | |||
| Change in fair value | ||||
| Balance - June 30, 2025 | $ | |||
| Exercise of warrants | ( | ) | ||
| Change in fair value | ( | ) | ||
| Balance – September 30, 2025 | $ |
| Balance - January 1, 2026 | $ | |||
| Change in fair value | ||||
| Balance - March 31, 2026 | $ | |||
| Exercise of warrants | ( | ) | ||
| Change in fair value | ( | ) | ||
| Balance - June 30, 2026 | $ | |||
| Change in fair value | ( | ) | ||
| Expiration of Angel Warrants | ( | ) | ||
| Balance – September 30, 2026 | $ |
Both observable and unobservable inputs were used to determine the fair value of warrants that the Company has classified within the Level 3 category. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long-dated volatilities) inputs.
The following table provides quantitative information regarding Level 3 fair value measurements inputs at their measurement:
| September 30, 2026 | ||||||||||||||||
| Investor Warrants | Avenue Warrants | Hudson Warrants | Dominari Warrants(3) | |||||||||||||
| Valuation Method | Monte Carlo | Black Scholes | Monte Carlo | Monte Carlo | ||||||||||||
| Strike price (per share) | $ | $ | $ | $ | ||||||||||||
| Term (years)(1) | ||||||||||||||||
| Volatility (annual) | % | % | % | % | ||||||||||||
| Risk-free rate | % | % | % | % | ||||||||||||
| Dividend yield (per share) | % | % | % | % | ||||||||||||
| Probability assessment(2) | % | % | % | % | ||||||||||||
14
| December 31, 2025 | ||||||||||||||||||||
| Angel Warrants | Investor Warrants | Avenue Warrants | Hudson Warrants | Dominari Warrants(3) | ||||||||||||||||
| Valuation Method | Black Scholes | Monte Carlo | Black Scholes | Monte Carlo | Monte Carlo | |||||||||||||||
| Strike price (per share) | $ | $ | $ | $ | $ | |||||||||||||||
| Term (years)(1) | ||||||||||||||||||||
| Volatility (annual) | % | % | % | % | % | |||||||||||||||
| Risk-free rate | % | % | % | % | % | |||||||||||||||
| Dividend yield (per share) | % | % | % | % | % | |||||||||||||||
| Probability assessment(2) | N/A | % | % | % | % | |||||||||||||||
| (1) |
| (2) |
| (3) |
8. COMMITMENTS AND CONTINGENCIES
Leases
The Company leases office space for its corporate headquarters in Dallas, Texas under a single operating lease that expires in February 2028. As of September 30, 2026, remaining undiscounted lease payments were $
Purchase Commitments
In June 2026, the Company issued a purchase order to its contract manufacturer for 30 DeepView Systems with a total value of approximately $
Legal Matters
The Company is not a party to any material legal proceedings or pending claims. From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities, none of which we believe are material or would be expected to have, individually or in the aggregate, a material adverse effect on our business, financial condition, cash flows or results of operations.
9. INCOME TAXES
The Company is subject to taxation in the United States, in various state and local jurisdictions, and in the United Kingdom. The current income tax expense recorded in each period presented relates principally to the Texas franchise tax, which is based on taxable margin, a measure derived from revenue, rather than on taxable income.
The Company recorded an income tax benefit of $
The provision for income taxes for interim periods is determined using an estimate of the Company’s annual effective tax rate, adjusted for discrete items arising in the period. The Company’s effective tax rate differs from the U.S. federal statutory rate of
There have been no material changes to the Company’s deferred tax assets, valuation allowance or unrecognized tax benefits since December 31, 2025. The Company evaluates its tax positions on a quarterly basis and revises its estimates as appropriate.
15
10. STOCKHOLDERS’ DEFICIT
The Company’s certificate of incorporation, as amended and restated, authorizes the issuance of
During the nine months ended September 30, 2026,
During the nine months ended September 30, 2026,
The Company is party to a standby equity purchase agreement with YA II PN, Ltd., an affiliate of Yorkville Advisors Global, LP (the “Yorkville SEPA”), under which the Company may, at its option and subject to the conditions and limitations of that agreement, sell shares of Common Stock to Yorkville from time to time. On November 13, 2026, the Yorkville SEPA was amended to extend its term through November 2028 (see Note 14). Shares sold under the Yorkville SEPA are issued at a discount to prevailing market prices, and the Company’s ability to draw on the facility is limited by the number of shares registered for resale, by ownership limitations applicable to Yorkville and by the Company’s ability to satisfy the conditions to each advance.
As of September 30, 2026,
11. STOCK-BASED COMPENSATION
As of September 30, 2026, there were
Restricted Stock Units
In April 2026, the Company granted
A summary of RSU activities for the nine months ended September 30, 2026 are presented below:
| Number of Shares | Weighted Average Grant Date Fair Value per Share | |||||||
| Nonvested as of January 1, 2026 | $ | |||||||
| Granted | $ | |||||||
| Vested | ( | ) | $ | |||||
| Forfeited | - | $ | - | |||||
| Nonvested as of September 30, 2026 | $ | |||||||
As of September 30, 2026, total unrecognized compensation expense related to restricted stock units was $
16
Stock Options
A summary of stock options activity for the nine months ended September 30, 2026 is presented below:
| Stock Options | Weighted Average Exercise Price | Weighted Average Remaining Contractual Life (in years) | Aggregate Intrinsic Value (in thousands) | |||||||||||||
| Outstanding at January 1, 2026 | $ | $ | ||||||||||||||
| Options granted | $ | |||||||||||||||
| Options forfeited | ( | ) | $ | |||||||||||||
| Options cancelled | ( | ) | $ | |||||||||||||
| Options exercised | ( | ) | $ | |||||||||||||
| Outstanding as of September 30, 2026 | $ | $ | ||||||||||||||
| Options vested and exercisable as of September 30, 2026 | $ | $ | ||||||||||||||
As of September 30, 2026, total unrecognized compensation expense related to stock options was $
Stock-based compensation expense, by expense category, during the three and nine months ended September 30, 2026 and 2025 consisted of the following (in thousands):
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Research and development | $ | $ | $ | $ | ||||||||||||
| General and administrative | ||||||||||||||||
| Selling and marketing | ( | ) | ||||||||||||||
| Total stock-based compensation expense | $ | $ | $ | $ | ||||||||||||
12. NET (LOSS) INCOME PER COMMON SHARE
The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders for the periods presented (in thousands, except share and per share amounts):
| Three Months Ended September 30 | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Numerator: | ||||||||||||||||
| Net loss attributable to common stockholders | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Denominator: | ||||||||||||||||
| Weighted average shares of common stock - basic and diluted | ||||||||||||||||
| Net loss per share attributable to common stockholders, basic and diluted | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
17
The table below summarizes potentially dilutive securities that were excluded from the above computation of net loss per common share as of the periods presented because including them would be anti-dilutive.
| As of September 30, | ||||||||
| 2026 | 2025 | |||||||
| Common stock options | ||||||||
| Common stock warrants | ||||||||
| Unvested restricted stock units | ||||||||
| Convertible notes payable | ||||||||
| Total | ||||||||
13. SEGMENT INFORMATION
Operating segments are defined as components of an enterprise for which separate and discrete information is available for evaluation by the chief operating decision-maker (the “CODM”) in deciding how to allocate resources and assess performance. Through March 31, 2026 the CODM was the Chairman of the Board in conjunction with the Company’s executive management team as they managed the Company’s operations on an aggregate basis for the purpose of allocating resources. Beginning on April 1, 2026, in connection with the appointment of a new Chief Executive Officer (“CEO”), the Company determined that its CEO is the CODM as he has ultimate decision-making authority over the Company’s operations, regulatory affairs, commercial strategy, and back-office (finance, accounting, and administrative) functions, which are the Company’s key operating departments. The CODM is the individual who regularly reviews the Company’s consolidated operating results, assesses performance against budget, and determines how the Company’s capital and personnel resources are allocated across these functions.
The Company continues to have one operating segment. The accounting policies of the Company’s single operating and reportable segment are the same as those described in the summary of significant accounting policies.
The Company’s method for measuring profitability includes net loss, which
14. SUBSEQUENT EVENTS
On November 12, 2026, the Company granted options to purchase
On November 13, 2026, the Company amended the Yorkville SEPA to extend its term from March 2027 through November 2028 and to provide for the sale of up to $
18
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
You should read the following discussion and analysis of our financial condition and results of operations together with the unaudited condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q and with our Annual Report on Form 10-K for the year ended December 31, 2025 (the “2025 Annual Report”). Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the section titled “Risk Factors,” in our 2025 Annual Report and in other reports we have filed or may file with the SEC, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.
Overview
We are an artificial intelligence (“AI”) company focused on predictive medical diagnostics. We operate in one segment. Currently, we are devoting substantially all of our efforts towards research and development of our DeepView System, an internally developed multi-spectral imaging device that has previously received FDA breakthrough device designation status for an earlier version. On May 26, 2026, the FDA granted De Novo classification for the DeepView System for the burn indication, which authorizes the Company to commence commercial distribution activities in the United States. Given our receipt of the UKCA mark for the burn indication, we also expect to begin commercialization activities in the United Kingdom in the near term. Our DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing “Day One” healing assessments. DeepView’s output is specifically engineered to allow the physician to make a more accurate, timely and informed decision regarding the treatment of the patient’s wound. Our focus has been on the burn indication which is supported by the Biomedical Advanced Research and Development Authority (“BARDA”) through the PBS BARDA Contract.
For burn wounds, a non-healing assessment could aid the clinician in making an immediate and objective determination for appropriate candidates for surgery, as well as determining what specific areas of the burn wound will require excision and skin grafting. The Company has completed the enrollment of 164 patients, including 49 pediatric subjects, representing the full enrollment requirements in its validation study for the De Novo submission. In participants, the DeepView System has shown superiority in sensitivity and met non-inferiority margin in specificity compared to clinician assessment. These findings were corroborated by the AI model’s cross-validation in identifying non-healing burn regions. This represents a significant improvement above the diagnostic accuracy of burn physicians assessing the same population. In addition to our validation study, we have conducted three large clinical studies with multiple sites across the United States, enrolling more than 400 patients, including adult and pediatric burn patients.
We have not generated any product revenue to date. We have received substantial support from the U.S. government for our DeepView System’s application for burn wounds, particularly from BARDA, which is part of the HHS Office of the Assistant Secretary for Preparedness and Response in the United States, established to aid in securing the United States from chemical, biological, radiological, and nuclear threats, as well as from pandemic influenza and emerging infectious diseases. We have also received funding from the National Science Foundation, the National Institute of Health and the Defense Health Agency (the “DHA”). Since 2013, we have been awarded approximately $282.5 million in funding from government contracts, substantially all of which is from BARDA, which accounts for $272.9 million. This has allowed us to develop our technology and further our clinical trials.
In September 2023, we executed our third contract with BARDA for a multi-year Project BioShield (“PBS”) agreement, valued at up to approximately $150.0 million (the “PBS BARDA Contract”). This included an initial award of approximately $54.9 million to support the clinical validation study and the distribution of up to 30 DeepView Systems in various burn centers and emergency departments to support our validation study and approximately another $95.1 million for further follow-on development and procurement activities related to the DeepView System. The funding also supported the Company’s FDA De Novo submission of our DeepView AI – Burn software, which was completed on June 30, 2025. In March 2026, BARDA exercised a portion of its contractual options under the contract, providing the Company with (i) a no-cost extension of the base phase of the contract from March 2026 to June 2026 and (ii) accelerated funding of approximately $31.7 million for further follow-on development and procurement activities related to the DeepView System. The contract continues to provide additional options, similar to our prior BARDA contracts, with an additional total value of approximately $63.4 million which can be exercised for additional product development, and the expanded procurement and deployment of DeepView Systems at emergency rooms, trauma and burn centers. These deployments will enable the Company to conduct health economic and outcome research studies to support the broader clinical adoption of the DeepView System. As part of this funding advance, the Company has committed to fund $9.7 million of the total overall development costs associated with these feature advancements. This contract funding is non-dilutive to our shareholders, and we believe it validates the important nature of our mission and technology.
19
In addition to our PBS BARDA Contract, we received a $4.0 million grant award from the Medical Technology Enterprise Consortium (“MTEC”) in April 2023, which, building on prior awards from the DHA, is to be used to support military battlefield burn evaluation via a handheld version of the DeepView System device (the “MTEC Agreement”). In August 2024, the MTEC award was increased to $4.9 million and was extended to run through December 2025 with funding dependent on various milestones. In December 2025, the MTEC Agreement was extended through December 31, 2026. The MTEC program was completed in October 2026. In March 2024, we received an additional $0.5 million award from the DHA to further this development, bringing the total value of our DHA awards supporting the handheld device to approximately $2.8 million.
As part of our commercialization strategy, we are pursuing reimbursement pathways for the DeepView System in both inpatient and outpatient settings. In October 2026, we submitted a New Technology Add-On Payment (“NTAP”) application to the Centers for Medicare & Medicaid Services (“CMS”) for the DeepView System under the alternative pathway. We anticipate a final determination from CMS regarding the NTAP application in August 2027. If approved, NTAP payment status would generally become available beginning in October 2027 and continue for approximately three years. In November 2026, CMS recognized DeepView as software as a medical service (“SaMS”) for outpatient reimbursement and assigned it to New Technology Ambulatory Payment Classification (“NT-APC”) 1504.
Once commercialized, we anticipate that the DeepView System will have two revenue streams, a software as a medical device (“SaMD”) model, and an imaging device component. The SaMD model applies a SaaS (software as a service) treatment for the DeepView System which will feature a software licensing fee that includes maintenance, image hosting, and access to algorithm updates. The proprietary imaging device accesses AI algorithms and is a universal platform to house multiple clinical applications. Pricing for these components will be evaluated and strategically set per country and site-of-service for heightened customer adoption.
Key Factors that May Influence Future Results of Operations
Our financial results of operations may not be comparable from period to period due to several factors. Key factors affecting our results of operations are summarized below.
Revenue Sources. As a pre-commercialization company, we currently generate revenue almost exclusively from two U.S. governmental agencies. We are highly dependent upon the continuation of the existing U.S. governmental contract awards, as well as future governmental procurement or other awards. Our operating results may not be comparable between periods as the timing and amount of awards or procurements from the U.S. government may be inconsistent with the timing of prior awards and the phasing of the development study schedules may be different. Our revenues may continue to be almost exclusively dependent upon the terms of those awards.
Operating Expenses. Following regulatory approval of the DeepView System, we expect operating expenses to increase as we invest in commercialization activities, including sales and marketing, manufacturing scale-up, and personnel growth. Operating expenses may fluctuate from period to period based on the timing of commercialization initiatives, product enhancements, hiring activities, and other strategic investments, which may impact the comparability of our results of operations.
Gross Margin. When we begin commercial sales of the DeepView System, we may need to determine lower pricing and incentives to accelerate adoption and implementation of the DeepView System, which may negatively impact future revenue and gross margin percentages.
20
Managing our Supply Chain. We are reliant on contract manufacturers and suppliers to produce our components and finished products. While we have not experienced disruptions in our current limited production, certain components may be subject to longer lead times, which may affect the timing and cost of our production activities.
Components of Consolidated Statements of Operations
Research and Development Revenue
To date, we have not generated any revenues from the sale or license of our products. Our primary source of revenue is research and development revenue. Currently, we are highly dependent upon the reimbursements from BARDA for the burn diagnostic testing of our DeepView System and other U.S. government awards. The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers. Our research and development revenue is affected by the amount of research and development that is expended each month with respect to our contract with BARDA and other U.S. governmental contract awards, such as our grant under the MTEC Agreement which we earn based on the achievement of milestones and performance milestones. Our revenue growth is dependent upon a number of factors, including expanding the research and development activities under the PBS BARDA Contract, research and development reimbursed expenses relating to other contract awards from U.S. governmental agencies and the intended future commercial sales of our DeepView System. See “Liquidity and Capital Resources” for additional information.
Cost of Revenue
Our cost of revenues consists primarily of direct and indirect costs associated with the research and development expenses relating to the BARDA and MTEC contracts. Our revenue costs are affected by the extent of research and development expenses as well as expansion of work on other U.S. governmental projects and the expanded applications for our DeepView System.
Gross Profit
Gross profit may vary from period-to-period and is primarily affected by the current reimbursement rates under the PBS BARDA Contract and other U.S. governmental contract awards. These reimbursement rates are fixed under the PBS BARDA Contract. Under the current PBS BARDA Contract, which does not include a fee component, our gross profit reflects these reimbursement rates applied to allowable costs, less the portion of costs we bear under the contract’s cost-share provisions. Under the other fixed fee U.S. governmental contract awards our gross profit corresponds to the achievement of pre-determined milestones.
Operating Costs and Expenses
Operating costs and expenses consist of research and development, general and administrative and selling and marketing expenses. These expenses primarily relate to salaries and related costs of our organization’s support and operations staff, consulting fees, rent, insurance and office expenses, and our non-revenue generating research and development expenses, primarily related to salaries and related costs and consulting fees.
Other income (expense)
Other income (expense) consists of net interest expense, financing related costs related to the Avenue Financing, fees related to the Hudson Bay Financing, change in the fair value of warrant liability, and foreign exchange transaction gains/losses. Historic foreign exchange transaction loss primarily relates to changes in the exchange rate between the U.S. dollar and the British pound sterling for our deposit accounts that are denominated in British pound sterling. In addition, this amount includes costs associated with buying British pound sterling for payment of our employees and vendors in the UK.
21
Results of Operations
The following table summarizes our results of operations for the three and nine months ended September 30, 2026 and 2025 (in thousands):
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| (In thousands) | ||||||||||||||||
| Research and development revenue | $ | 2,856 | $ | 3,792 | $ | 10,371 | $ | 15,564 | ||||||||
| Cost of revenue | (2,078 | ) | (2,171 | ) | (6,453 | ) | (8,485 | ) | ||||||||
| Gross profit | 778 | 1,621 | 3,918 | 7,079 | ||||||||||||
| Operating costs and expenses: | ||||||||||||||||
| Research and development | 1,989 | 1,531 | 5,247 | 4,301 | ||||||||||||
| General and administrative | 2,341 | 3,064 | 7,657 | 8,124 | ||||||||||||
| Selling and marketing | 414 | 367 | 1,275 | 1,014 | ||||||||||||
| Total operating costs and expenses | 4,744 | 4,962 | 14,179 | 13,439 | ||||||||||||
| Operating loss | (3,966 | ) | (3,341 | ) | (10,261 | ) | (6,360 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Net interest expense | (586 | ) | (464 | ) | (1,401 | ) | (881 | ) | ||||||||
| Financing related costs | (1 | ) | - | (13 | ) | (585 | ) | |||||||||
| Change in fair value of warrant liability | 825 | 264 | 534 | (932 | ) | |||||||||||
| Change in fair value of notes payable | - | - | - | 220 | ||||||||||||
| Foreign exchange transaction loss, net | (6 | ) | (9 | ) | (21 | ) | (31 | ) | ||||||||
| Total other income (expense), net | 232 | (209 | ) | (901 | ) | (2,209 | ) | |||||||||
| Loss before income taxes | (3,734 | ) | (3,550 | ) | (11,162 | ) | (8,569 | ) | ||||||||
| Income tax benefit (provision) | 78 | (2 | ) | (82 | ) | (54 | ) | |||||||||
| Net loss | $ | (3,656 | ) | $ | (3,552 | ) | $ | (11,244 | ) | $ | (8,623 | ) | ||||
Research and Development Revenue
Research and development revenue was $2.9 million and $10.4 million for the three and nine months ended September 30, 2026, respectively, a decrease of 24.7% and 33.4%, respectively compared to the same periods in 2025, reflecting the reduction in reimbursed costs under the PBS BARDA Contract following the FDA’s De Novo authorization of the DeepView System, as the remaining scope of work narrowed to specific development projects, together with the cost-share provisions applicable to the follow-on development phase of that contract. Revenue from the Company’s other U.S. governmental contracts decreased to $0.1 million and $1.0 million for the three and nine months ended September 30, 2026, respectively, from $0.4 million and $1.1 million for the same periods in 2025, as work on the handheld device under the MTEC Agreement was completed.
For the three and nine months ended September 30, 2026 and 2025, the Company’s revenues disaggregated by the major sources were as follows (in thousands):
| Three Months Ended September 30, | Change in | Nine Months Ended September 30, | Change in | |||||||||||||||||||||||||||||
| 2026 | 2025 | $ | % | 2026 | 2025 | $ | % | |||||||||||||||||||||||||
| (In thousands, except percentages) | ||||||||||||||||||||||||||||||||
| BARDA | $ | 2,745 | $ | 3,442 | $ | (697 | ) | (20.2 | )% | $ | 9,334 | $ | 14,472 | $ | (5,138 | ) | (35.5 | )% | ||||||||||||||
| Other U.S. governmental authorities | 111 | 350 | (239 | ) | (68.3 | )% | 1,037 | 1,092 | (55 | ) | (5.0 | )% | ||||||||||||||||||||
| Total research and development revenue | $ | 2,856 | $ | 3,792 | $ | (936 | ) | (24.7 | )% | $ | 10,371 | $ | 15,564 | $ | (5,193 | ) | (33.4 | )% | ||||||||||||||
22
Cost of Revenues and Gross Profit
Cost of revenue for the three and nine months ended September 30, 2026 was $2.1 million and $6.5 million, respectively, a decrease of 4.3% and 23.9%, respectively, compared to the same periods in 2025, due to the cost share provisions applicable to the follow-on development phase of the PBS BARDA Contract, under which the Company funds a portion of the development costs it incurs.
Gross margin for the three and nine months ended September 30, 2026 was 27.2% and 37.8%, respectively, a decrease of 15.5 percentage points and 7.7 percentage points, respectively, as compared to the same periods in 2025, reflecting the cost-share provisions of the follow-on development phase of the PBS BARDA Contract, under which the Company continues to incur development costs that are not fully reimbursable, and a lower margin on the Company’s fixed-fee MTEC contract. For the nine months ended September 30, 2026, the decrease primarily reflects the lower proportion of costs billed under the follow-on development phase of that contract, partially offset by the higher gross margin realized in the first quarter of 2026 prior to the commencement of that phase. The third quarter of 2026 was the first full quarter under the follow-on development phase, following completion of the base phase in June 2026, and therefore reflects the full effect of the cost-share provisions.
Operating Expense
Research and development expense was $2.0 million and $5.2 million for the three and nine months ended September 30, 2026, respectively, an increase of 29.9% and 22.0%, respectively, as compared to the same period in 2025 due to an increase in non-revenue generating research and development activities, primarily the U.K. heads, hands and feet labeling study.
General and administrative expense was $2.3 million and $7.7 million for the three and nine months ended September 30, 2026, respectively, a decrease of 23.6% and 5.7%, respectively, as compared to the same period in 2025 due to lower legal fees and related professional services.
Selling and marketing expense was $0.4 million and $1.3 million for the three and nine months ended September 30, 2026, respectively, an increase of 12.8% and 25.7%, respectively, as compared to the same period in 2025 due to increased sales and marketing activities in advance of first commercial sales, including a third-party pricing study.
Other income (expense)
Net interest expense for the three and nine months ended September 30, 2026 primarily relates to interest expense and amortization of the debt discount associated with the Avenue Financing as well as costs related to the Company’s insurance policy financing.
Financing related costs increased $1 thousand and decreased $0.6 million, respectively, for the three and nine months ended September 30, 2026, as compared to the comparable period in 2025 primarily due to the elimination of the expenses relating to the Company’s prior financings that were expensed during fiscal year 2025.
Change in fair value of warrant liability reflected a favorable change of $0.6 million and $1.5 million, respectively, for the three and nine months ended September 30, 2026 as compared to the comparable periods in 2025. Change in fair value of warrant liability was a benefit of $0.8 million and $0.5 million, respectively, for the three and nine months ended September 30, 2026, as compared to a benefit of $0.3 million and expense of $0.9 million, respectively, for same periods in 2025. The changes reflect fluctuations in the fair value of the Company’s warrants during the three- and nine-month periods ended September 30, 2026. The Company’s warrants are classified as liabilities and remeasured to fair value at each reporting period, with changes recognized in net loss. As a result, fluctuations in the warrant price of Public Warrants and fluctuations in the fair value of other outstanding warrants may cause significant non-cash gains or losses, leading to volatility in reported net loss.
23
Liquidity and Capital Resources
Sources of Liquidity
As of September 30, 2026 and December 31, 2025, the Company had $11.2 million and $15.4 million, respectively, in cash and cash equivalents, and an accumulated deficit of $67.0 million and $55.8 million, respectively. As of September 30, 2026 and December 31, 2025, the Company had $15.5 million and $8.4 million, respectively, of debt outstanding of which $7.4 million and $5.5 million represented long-term debt as of such periods, respectively. The Company also had $1.2 million of remaining undiscounted operating lease payments as of September 30, 2026, extending through February 2028.
BARDA has committed $86.6 million to date under the Company’s PBS BARDA Contract, which has an overall value of approximately $150 million. As of September 30, 2026, $24.8 million of committed funding remained to be performed (see Note 3); and the Company funds a portion of development costs under the current phase.
The Company also has an effective shelf registration statement on Form S-3 with an aggregate capacity of $50.0 million, of which approximately $12.1 million had been utilized as of September 30, 2026. Because the aggregate market value of the Common Stock held by non-affiliates is less than $75.0 million, the Company’s ability to sell securities in primary offerings under that registration statement is limited, in any twelve-month period, to one-third of the aggregate market value of the Common Stock held by non-affiliates. As of November 16, 2026, approximately $16.1 million remained available to the Company under that limitation based on the Company’s public float. The amount available is not fixed and will increase or decrease in concert with the Company’s share price and public float.
As of September 30, 2026, based on our current operating plan, our cash and cash equivalents of $11.2 million, together with the $24.8 million of committed funding remaining under the PBS BARDA Contract, the 3,657,945 shares remaining registered for resale under the Yorkville SEPA, and up to $15.0 million of additional sales under the Yorkville SEPA as amended on November 13, 2026, subject to the applicable purchase price, ownership cap, exchange cap, and shelf capacity limitations, provide sufficient liquidity to fund operations and meet our obligations as they become due for at least one year after the date the condensed consolidated financial statements are issued. We expect to fund the Avenue principal payments in part through sales under the Yorkville SEPA. Sales under the Yorkville SEPA are made at 97% of the lowest daily volume-weighted average price during a three-trading-day pricing period, and are limited by Yorkville’s 4.99% ownership limitation, by exchange caps of 6,369,937 shares in total for the shares registered for resale (of which 3,657,945 shares remain available) and 6,433,767 shares for sales under the amended Yorkville SEPA, which may be reduced by shares issued in transactions aggregated with it under Nasdaq rules, and by the amount available under our Form S-3, and depend on the price of our common stock, and there is no assurance that we will be able to use the full commitment. We have based this determination on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. Changing circumstances could also cause us to consume capital significantly faster than we currently anticipate, and we may need to raise capital sooner or in greater amounts than currently expected because of circumstances beyond our control. To the extent additional capital is necessary, there are no assurances that we will be able to raise additional capital on favorable terms or at all, and therefore we may not be able to execute our business plans and the continued work on indications beyond expanding our burn indication.
Cash Flows
The following table summarizes our cash flows for the nine months ended September 30, 2026 and 2025 (in thousands):
| Nine Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| Net cash used in operating activities | $ | (10,472 | ) | $ | (7,368 | ) | ||
| Net cash provided by financing activities | 6,313 | 12,670 | ||||||
Cash Flows Used in Operating Activities
Net cash used in operating activities increased to $10.5 million for the nine months ended September 30, 2026, as compared to $7.4 million for the nine months ended September 30, 2025, primarily attributable to the higher net loss and changes in operating assets and liabilities, including the absence of the significant accounts receivable collections realized during the 2025 period.
24
Cash Flows Provided by Financing Activities
Net cash provided by financing activities for the nine months ended September 30, 2026 reflects proceeds received from Avenue Financing and stock option and warrant exercises, offset by repayments of insurance notes payable. Net cash provided by financing activities of $12.7 million for the nine months ended September 30, 2025 was primarily attributable to proceeds from the Avenue Financing of $8.3 million, proceeds from the exercise of common stock warrants of $2.0 million and the attendant equity raise of $3.1 million partially, offset by the loan repayments on the Yorkville debt facility.
Current Indebtedness
The Avenue Financing provided for aggregate borrowings of up to $15.0 million. The Company initially drew down $8.5 million in March 2025. On June 18, 2026, the Company drew down the second financing tranche under the Avenue Financing following the achievement of the required funding conditions. The Company received net proceeds of $6.5 million. Following the 24-month interest-only period, principal is repaid in twelve equal monthly installments of $1.25 million beginning in April 2027, with the final payment due at maturity.
The loans under the Avenue Financing mature on March 1, 2028, with an interest-only payment period of no less than 15 months, which has been extended to 24 months upon the achievement of certain milestones prior to the end of such 15-month period as described in the Tranche 2 Milestone Date (as defined in the Supplement to the Loan Agreement). The Company achieved the Tranche 2 Milestone during the nine months ended September 30, 2026, and as such, the interest-only period was extended to 24 months.
The Avenue Financing also includes warrant coverage equal to 8.5% of the total funding commitment from Avenue, with an exercise price equal to $1.66.
Related Party Transactions
Other than compensation arrangements with our directors and executive officers in the ordinary course of business, the Company did not have any related party transactions during the nine months ended September 30, 2026.
Off-Balance Sheet Arrangements
During the periods presented, we did not have any off-balance sheet arrangements, as defined in Item 303(a)(4)(ii) of SEC Regulation S-K.
Critical Accounting Policies
Our management’s discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of these condensed consolidated financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, costs and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates which include, but are not limited to, revenue recognition, warrant liabilities, fair value of certain debt, stock-based compensation expense, stock issued for transaction costs, the net realizable value of inventory, right-of-use assets, and income tax valuation allowances. We base our estimates on historical experience, known trends and events and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates under different assumptions or conditions.
Our critical accounting policies are described under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Critical Accounting Policies” in our Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on March 25, 2026. During the nine months ended September 30, 2026, there were no material changes to our critical accounting policies from those previously disclosed.
25
Recent Accounting Pronouncements
See Note 2, Recent Accounting Pronouncements, of the notes to our condensed consolidated financial statements included elsewhere in this Form 10-Q for recently adopted accounting standards and recently issued accounting standards as of the dates of the statement of financial position included in this Form 10-Q.
Emerging Growth Company
We are an emerging growth company, as defined in the JOBS Act. The JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of some accounting standards until those standards would otherwise apply to private companies. We have elected to use the extended transition period under the JOBS Act for the adoption of certain accounting standards until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply more promptly with new or revised accounting pronouncements as of public company effective dates.
In addition, as an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. These provisions include:
| ● | being permitted to present only two years of audited consolidated financial statements in addition to any required unaudited interim consolidated financial statements, with correspondingly reduced disclosure in the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations”; |
| ● | an exception from compliance with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended; |
| ● | reduced disclosure about our executive compensation arrangements in our periodic reports, proxy statements and registration statements; |
| ● | exemptions from the requirements of holding non-binding advisory votes on executive compensation or golden parachute arrangements; and |
We may take advantage of these provisions until the last day of the fiscal year ending after the fifth anniversary of the Company’s initial public offering or such earlier time that we no longer qualify as an emerging growth company. We will cease to qualify as an emerging growth company on December 31, 2026. We may choose to take advantage of some but not all of these reduced reporting burdens. Accordingly, the information contained herein may be different than you might obtain from other public companies in which you hold equity interests.
We are also a “smaller reporting company.” If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, we may choose to present only the two most recent fiscal years of audited consolidated financial statements in our Annual Report and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
Pursuant to Item 305(e) of Regulation S-K, the Company is a smaller reporting company and is not required to provide the information required by this Item.
26
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as that term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act). Our management, under the supervision of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of the end of the period covered by this Quarterly Report on Form 10-Q.
Material Weakness: Our financial statement close process controls, including controls over account reconciliations, transaction processing, and financial reporting review, did not operate consistently or with sufficient precision to ensure timely performance and review, including appropriate oversight of financial statement reporting. In conducting our evaluation, management used the updated framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control-Integrated Framework (2013). Disclosure controls and procedures are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.
Based on that evaluation, management concluded that, as of September 30, 2026, our disclosure controls and procedures were not effective due to the material weakness in internal control over financial reporting described below. As discussed in Item 9A of our Form 10-K for the year ended December 31, 2025, we identified a material weakness in our internal control over financial reporting as well as a lack of effective controls over the COSO principles including control environment, risk assessment, control activities, information and communications and monitoring as of December 31, 2025.
Remediation Plan for Material Weakness
Remediation generally requires making changes to how controls are designed and implemented and then adhering to those changes for a sufficient period of time such that the effectiveness of those changes is demonstrated with an appropriate amount of consistency. In response to the material weakness, we implemented, and are continuing to implement and monitor, measures designed to improve our internal control over financial reporting. These efforts include:
| ● | appointing a new Chief Financial Officer with extensive technical accounting and public company financial reporting experience, with remediation of the material weakness as a specific objective, and supplemented accounting personnel to address capacity gaps; |
| ● | completing a full-scope documentation and assessment of the design of our internal control over financial reporting, including controls over the financial statement close process and account reconciliations; | |
| ● | during 2026, implementing a monthly account reconciliation process supported by a standardized reconciliation tracker, with documented preparer and reviewer sign-off and Chief Financial Officer review of key reconciliations, quarterly certifications from control owners, and an updated risk and control matrix; and | |
| ● | with appropriate accounting staffing now in place, engaging external specialists where their use is warranted, including in the areas of technical accounting, SEC reporting, valuation and tax. Management retains responsibility for the work of those specialists, evaluating their qualifications and objectivity and reviewing and approving their analyses and conclusions. |
The measures we implemented are subject to continued management review supported by confirmation and testing, as well as audit committee oversight. Management and the Audit Committee remain committed to the implementation of remediation efforts to address the material weakness. We will continue to implement measures to remedy our internal control deficiencies, though there can be no assurance that our efforts will be successful or avoid potential future material weaknesses. In addition, until remediation steps have been completed and are operated for a sufficient period of time, and subsequent evaluation of their effectiveness is completed, the material weaknesses previously disclosed, and as described above, will continue to exist. These controls have been implemented, and management has performed its own testing of their operation for the first and second quarters of 2026 and will test the third and fourth quarters. Management expects that this testing will support a conclusion that the controls are appropriately designed and operating effectively and that the material weakness has been remediated.
Changes in Internal Control over Financial Reporting
Except for the remediation efforts in connection with the material weakness described above, there were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) that occurred during the quarter ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
27
PART II - OTHER INFORMATION
Item 1. Legal Proceedings
The Company is not a party to any material legal proceedings or pending claims. From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities, none of which we believe are material or would be expected to have, individually or in the aggregate, a material adverse effect on our business, financial condition, cash flows or results of operations.
Item 1A. Risk Factors
Factors that could cause our actual results to differ materially from those in this Quarterly Report include the risk factors described in our Annual Report on Form 10-K filed with the SEC on March 25, 2026 and in our Registration Statement on Form S-1 (Registration No. 333-278610), including those relating to our standby equity purchase agreement with Yorkville. Any of those factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations. As of the date of this Quarterly Report, except as set forth below, there have been no material changes to the risk factors disclosed in our Annual Report on Form 10-K filed with the SEC on March 25, 2026. We may disclose changes to such factors or disclose additional factors from time to time in our future filings with the SEC.
We rely on sales of our common stock under our standby equity purchase agreement with Yorkville (the “SEPA”) to fund a portion of our operations, and our ability to access those funds is subject to certain limitations and conditions.
Sales under the SEPA are priced at a discount to the market price of our common stock, and the amount we can sell depends on market conditions, the 19.99% exchange cap limitation under Nasdaq rules and the capacity under our shelf registration statement. As a result, we may not be able to access the full commitment when needed or at all.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
None.
Use of Proceeds
There has been no material change in the planned use of the proceeds from the Business Combination, as is described in the Company’s final prospectus (Registration No. 333-275218), as filed with the SEC on January 2, 2024. Additionally, there has been no material change in the planned use of proceeds from the Avenue Financing, as is described in the Company’s Current Report on Form 8-K as filed with the SEC on March 26, 2025 or the planned use of proceeds from the Hudson Financing, as described in the prospectus supplement to the Form S-3 (Registration No. 333-282681), filed on October 22, 2025.
Item 3. Defaults Upon Senior Securities
None.
28
Item 4. Mine Safety Disclosures
None.
Item 5. Other Information
Item 6. Exhibits
The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q:
| No. | Description of Exhibit | |
| 2.1 | Business Combination Agreement, dated as of April 11, 2023, by and among Rosecliff Acquisition Corp I, Ghost Merger Sub I Inc., Ghost Merger Sub II and Spectral MD Holdings Ltd. (incorporated by reference to the Company’s Form 8-K, filed with the SEC on April 17, 2023). | |
| 31.1* | Certification of Principal Executive Officer | |
| 31.2* | Certification of Chief Financial Officer (Principal Financial and Accounting Officer) | |
| 32** | 18 U.S.C. Section 1350 Certification | |
| 101.INS* | Inline XBRL Instance Document. | |
| 101.SCH* | Inline XBRL Taxonomy Extension Schema Document. | |
| 101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document. | |
| 101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document. | |
| 101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document. | |
| 101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document. | |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
| * | Filed herewith. |
| ** | Furnished herewith. |
29
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| SPECTRAL AI, INC. | ||
| Date: November 16, 2026 | By: | /s/ Vincent S. Capone |
| Name: | Vincent S. Capone | |
| Title: | Chief Executive Officer | |
| (Principal Executive Officer) | ||
| Date: November 16, 2026 | By: | /s/ David McGuire |
| Name: | David McGuire | |
| Title: | Chief Financial Officer | |
| (Principal Financial and Accounting Officer) | ||
30